NAVAMEDIC ASA financials
NAVAMEDIC ASA
529900LKVQOR2SRUJU71 | Line item | 2024 | 2023 |
|---|---|---|
| Income statement | ||
| Revenue | NOK 531.4M | NOK 512.0M |
| Employee benefits expense | NOK 70.3M | NOK 63.7M |
| Raw materials & consumables used | NOK 322.6M | NOK 312.9M |
| Depreciation & amortisation | NOK 10.5M | NOK 8.6M |
| Operating profit (EBIT) | NOK 31.8M | NOK 23.6M |
| Net finance income / (cost) | -NOK 33.4M | -NOK 29.7M |
| Finance costs | NOK 16.8M | NOK 14.3M |
| Profit before tax | -NOK 1.6M | -NOK 6.2M |
| Income tax expense | NOK 3.9M | NOK 7.5M |
| Profit for the year | -NOK 5.5M | -NOK 13.7M |
| Total comprehensive income | NOK 2.0M | -NOK 13.2M |
| Per share | ||
| Basic EPS | NOK -0.31 | NOK -0.79 |
| Diluted EPS | NOK -0.31 | NOK -0.79 |
| Cash flow statement | ||
| Net cash from operating activities | NOK 39.4M | NOK 2.2M |
| Net cash from investing activities | -NOK 2.8M | -NOK 104.6M |
| Net cash from financing activities | -NOK 37.7M | NOK 83.2M |
| Proceeds from borrowings | NOK 0 | NOK 145.1M |
| Repayments of borrowings | NOK 32.5M | NOK 54.3M |
| Lease liability payments | NOK 3.3M | NOK 2.6M |
| Balance sheet | ||
| Total assets | NOK 467.5M | NOK 507.3M |
| Non-current assets | NOK 267.5M | NOK 297.2M |
| Property, plant & equipment | NOK 4.5M | NOK 3.7M |
| Right-of-use assets | NOK 4.2M | NOK 6.1M |
| Intangible assets & goodwill | NOK 159.1M | NOK 156.7M |
| Current assets | NOK 200.0M | NOK 210.1M |
| Inventories | NOK 81.9M | NOK 105.2M |
| Trade & other receivables | NOK 55.9M | NOK 50.6M |
| Cash & equivalents | NOK 37.3M | NOK 38.0M |
| Total equity | NOK 216.7M | NOK 205.4M |
| Non-current liabilities | NOK 110.0M | NOK 112.6M |
| Long-term borrowings | NOK 78.6M | NOK 95.5M |
| Lease liabilities (non-current) | NOK 1.7M | NOK 3.9M |
| Current liabilities | NOK 140.8M | NOK 189.3M |
| Short-term borrowings | NOK 35.4M | NOK 51.1M |
| Lease liabilities (current) | NOK 2.9M | NOK 2.5M |
| Deferred tax liabilities | NOK 8.4M | NOK 9.3M |
| Derived metrics | ||
| Operating margin | 6.0% | 4.6% |
| Net margin | -1.0% | -2.7% |
| Return on equity | -2.5% | -6.7% |
| Cash conversion ratio | -7.17× | -0.16× |
| Other reported items | ||
| Adjustments For Decrease Increase In Inventories | NOK 17.5M | -NOK 23.8M |
| Adjustments For Decrease Increase In Trade and Other Receivables | -NOK 5.3M | -NOK 5.0M |
| Adjustments For Depreciation and Amortisation Expense and Impairment Loss Reversal of Impairment Loss Recognised In Profit Or Loss | NOK 40.3M | NOK 29.3M |
| Adjustments For Finance Income Cost | -NOK 643.0K | -NOK 5.8M |
| Adjustments For Increase Decrease In Trade and Other Payables | -NOK 18.0M | NOK 765.0K |
| Cash Advances and Loans Made To Other Parties Classified As Investing Activities | NOK 0 | NOK 5.0M |
| Comprehensive Income Attributable To Owners of Parent | NOK 2.0M | -NOK 13.2M |
| Current Loans and Receivables | NOK 0 | NOK 0 |
| Current Tax Assets Current | NOK 8.7M | NOK 14.9M |
| Current Tax Liabilities Current | NOK 5.2M | NOK 8.1M |
| Deferred Tax Assets | NOK 934.0K | NOK 930.0K |
| Depreciation Expense | NOK 4.3M | NOK 3.3M |
| Effect of Exchange Rate Changes On Cash and Cash Equivalents | NOK 412.0K | NOK 1.9M |
| Equity and Liabilities | NOK 467.5M | NOK 507.3M |
| Finance Income | NOK 3.1M | NOK 4.8M |
| Gain Loss Arising From Derecognition of Financial Assets Measured At Amortised Cost | NOK 13.7M | NOK 0 |
| Gains Losses On Exchange Differences On Translation Recognised In Profit Or Loss | -NOK 6.3M | NOK 5.9M |
| Gains Losses Recognised In Profit Or Loss Fair Value Measurement Assets | -NOK 1.6M | -NOK 8.7M |
| Impairment Loss Reversal of Impairment Loss Recognised In Profit Or Loss | NOK 25.6M | NOK 17.4M |
| Income Taxes Paid Refund Classified As Operating Activities | NOK 3.1M | NOK 5.1M |
| Increase Decrease In Cash and Cash Equivalents | -NOK 751.0K | -NOK 17.3M |
| Increase Decrease Through Sharebased Payment Transactions | NOK 3.4M | NOK 6.6M |
| Interest Paid Classified As Financing Activities | NOK 7.8M | NOK 7.2M |
| Interest Received Classified As Investing Activities | NOK 547.0K | NOK 614.0K |
| Issue of Equity | NOK 5.9M | NOK 2.3M |
| Issued Capital | NOK 13.1M | NOK 12.8M |
| Liabilities | NOK 250.8M | NOK 301.9M |
| Noncurrent Loans and Receivables | NOK 6.2M | NOK 32.2M |
| Other Adjustments For Noncash Items | NOK 3.4M | NOK 6.6M |
| Other Cash Payments To Acquire Equity Or Debt Instruments of Other Entities Classified As Investing Activities | NOK 0 | NOK 98.0M |
| Other Comprehensive Income | NOK 7.5M | NOK 502.0K |
| Other Comprehensive Income Net of Tax Exchange Differences On Translation | NOK 7.5M | NOK 502.0K |
| Other Current Financial Assets | NOK 16.2M | NOK 1.4M |
| Other Current Liabilities | NOK 47.0M | NOK 42.5M |
| Other Expense By Nature | NOK 92.1M | NOK 99.9M |
| Other Intangible Assets | NOK 92.6M | NOK 97.6M |
| Other Noncurrent Assets | NOK 14.9M | NOK 41.9M |
| Proceeds From Issuing Shares | NOK 5.9M | NOK 2.3M |
| Retained Earnings | NOK 5.4M | -NOK 16.0K |
| Share Premium | NOK 198.2M | NOK 192.6M |
| Trade and Other Current Payables To Trade Suppliers | NOK 50.3M | NOK 68.3M |
Every line item above is a fact tagged in NAVAMEDIC ASA's annual report
filed in the European Single Electronic Format (ESEF) under the IFRS
taxonomy (ifrs-full) — the income statement, balance sheet
and cash-flow statement as the filer reported them. Values are shown
as-is, in the reporting currency (NOK), without
rescaling; the row labels map to the underlying concept name (e.g.
Revenue → ifrs-full:Revenue, Operating profit →
ifrs-full:ProfitLossFromOperatingActivities, Diluted EPS →
ifrs-full:DilutedEarningsLossPerShare), and any concept
without a curated label is shown under “Other reported items” with its
de-camel-cased tag name. Only consolidated, default-member facts are
shown (segment / dimensional breakdowns are excluded).
“Derived metrics” (free cash flow, margins, ROE, …) are computed from those facts by the same model the U.S. financials pages use — not tagged by the filer.
Source: machine-readable OIM xBRL-JSON aggregated by filings.xbrl.org (XBRL International). Entity identity is resolved by LEI via the public-domain GLEIF register. This is reference data, not investment advice.